Novo Nordisk shares climbed after the U.S. Food and Drug Administration approved a new indication for the Danish drugmaker’s blockbuster Wegovy medicine to treat a serious fatty liver disease. Shares in Novo Nordisk rose as much as 5% in early European trading Monday,

Novo Nordisk launched its NovaCare pharmacy in March, offering Wegovy for $499 to patients willing to skip insurance and forego any reimbursement.

Canada has approved Novo Nordisk's (NOVOb.CO) diabetes drug, Ozempic, to cut chronic kidney disease progression and reduce the risk of kidney failure and heart-related deaths in type-2 diabetes patien...

The drugmaker says patients who pay for the medication on their own and don’t go through insurance can get monthly supplies for $499.